Inventor · disambiguated record
Carine Paturel
Also filed as: PATUREL CARINE
24 granted patents·28 pending applications·103 citations·filing 2002–2025
95Inventor score
Top patents by PatentIndex Score
52 records- 0196US11958907B2CD73 blockadeINNATE PHARMA·Filed 2020·Granted Apr 16, 2024·4 cites·21 claims
- 0295US11572410B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2020·Granted Feb 7, 2023·3 cites·5 claims
- 0394US10577419B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2015·Granted Mar 3, 2020·15 cites·10 claims
- 0493US10711063B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2015·Granted Jul 14, 2020·8 cites·13 claims
- 0592US10676523B2Treatment regimens using anti-NKG2A antibodiesINNATE PHARMA·Filed 2015·Granted Jun 9, 2020·7 cites·10 claims
- 0689US11377503B2Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptideINNATE PHARMA·Filed 2019·Granted Jul 5, 2022·3 cites·13 claims
- 0789US10870700B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2017·Granted Dec 22, 2020·6 cites·16 claims
- 0889US10766966B2CD73 blockadeINNATE PHARMA·Filed 2015·Granted Sep 8, 2020·5 cites·12 claims
- 0989US10246510B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2013·Granted Apr 2, 2019·9 cites·20 claims
- 1088US11858990B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2020·Granted Jan 2, 2024·2 cites·7 claims
- 1188US6875580B2Antibodies specific for plasmacytoid dendritic cellsSCHERING CORP·Filed 2004·Granted Apr 5, 2005·22 cites·6 claims
- 1284US2024368281A1Treatment regimens using anti-nkg2a antibodiesINNATE PHARMA·Filed 2024·Application pending·0 cites
- 1383US11130817B2CD73 blocking agentsINNATE PHARMA·Filed 2016·Granted Sep 28, 2021·3 cites·5 claims
- 1483US9388246B2TLR3 binding agentsGAUTHIER LAURENT·Filed 2011·Granted Jul 12, 2016·9 cites·55 claims
- 1580US2024124579A1Kir3dl2 binding agentsINNATE PHARMA·Filed 2023·Application pending·0 cites
- 1679US12202907B2Nucleic acids encoding and methods of producing proteins comprising antibody chainsINNATE PHARMA·Filed 2022·Granted Jan 21, 2025·0 cites·36 claims
- 1779US10736963B2Methods for detecting tissue infiltrating NK cellsINNATE PHARMA·Filed 2016·Granted Aug 11, 2020·2 cites·5 claims
- 1879US2024391999A1Treatment with anti-kir3dl2 agentsINNATE PHARMA·Filed 2024·Application pending·0 cites
- 1978US11377492B2NKp46 binding agentsINNATE PHARMA·Filed 2018·Granted Jul 5, 2022·1 cites·16 claims
- 2077US11578136B2Compositions and methods for treating cancerINNATE PHARMA·Filed 2018·Granted Feb 14, 2023·1 cites·12 claims
- 2176US2023235060A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2023·Application pending·0 cites
- 2274US12037392B2Treatment regimens using anti-NKG2A antibodiesINNATE PHARMA·Filed 2021·Granted Jul 16, 2024·0 cites·10 claims
- 2374US2023303691A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2023·Application pending·0 cites
- 2474US2010086560A1Chemokines as adjuvants of immune responseSCHERING CORP·Filed 2009·Application pending·0 cites
- 2573US8273541B2Compositions and methods for detecting TLR3CHEMIN KARINE·Filed 2009·Granted Sep 25, 2012·3 cites·14 claims
- 2673US2023340143A1Compositions and methods for treating cancerINNATE PHARMA·Filed 2023·Application pending·0 cites
- 2771US2025236678A1Compositions and methods for treating cancerINNATE PHARMA·Filed 2025·Application pending·0 cites
- 2870US12365731B2NKp46 binding agentsINNATE PHARMA·Filed 2022·Granted Jul 22, 2025·0 cites·9 claims
- 2970US2023099801A1Restoration of t cell activity via the cd39/cd73 axisINNATE PHARMA·Filed 2022·Application pending·0 cites
- 3068US11970535B2Treatment with anti-KIR3DL2 agentsINNATE PHARMA·Filed 2020·Granted Apr 30, 2024·0 cites·19 claims
- 3168US2007166280A1Chemokines as adjuvants of immune responseSCHERING CORP·Filed 2007·Application pending·0 cites
- 3267US2020299383A1Treatment regimens using anti-nkg2a antibodiesINNATE PHARMA·Filed 2020·Application pending·0 cites
- 3365US2022056145A1Anti-cd39 antibodiesOREGA BIOTECH·Filed 2021·Application pending·0 cites
- 3464US2021122821A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2020·Application pending·0 cites
- 3560US12448442B2Treatment of T cell lymphomaINNATE PHARMA·Filed 2021·Granted Oct 21, 2025·0 cites·12 claims
- 3659US2003077247A1Chemokines as adjuvants of immune responseSCHERING CORP·Filed 2002·Application pending·0 cites
- 3758US2019248895A1Treatment with anti-kir3dl2 agentsINNATE PHARMA·Filed 2017·Application pending·0 cites
- 3857US2019071514A1Anti-cd39 antibodiesINNATE PHARMA·Filed 2017·Application pending·0 cites
- 3957US2023340140A1Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimabINNATE PHARMA·Filed 2021·Application pending·0 cites
- 4055US2024270865A1Cancer treatment methods using anti-cd73 antibodiesINNATE PHARMA·Filed 2021·Application pending·0 cites
- 4153US2014234323A1Compositions and methods for detecting tlr3INNATE PHARMA·Filed 2014·Application pending·0 cites
- 4250US2011076296A1TLR3 Agonist CompositionsINNATE PHARMA SA·Filed 2009·Application pending·0 cites
- 4349US8715667B2Methods of treating patients having TLR3-positive cancerCHEMIN KARINE·Filed 2012·Granted May 6, 2014·0 cites·10 claims
- 4449US2019218308A1Restoration of t cell activity via the cd39/cd73 axisINNATE PHARMA·Filed 2019·Application pending·0 cites
- 4545US2019218304A1Potentiating the effect of atp releaseINNATE PHARMA·Filed 2019·Application pending·0 cites
- 4644US9944712B2TLR3 binding agentsINNATE PHARMA·Filed 2013·Granted Apr 17, 2018·0 cites·28 claims
- 4743US2016136272A1Methods for restoring corticosteroid sensitivityINNATE PHARMA·Filed 2014·Application pending·0 cites
- 4841US2016347853A1Tlr3 binding agentsINNATE PHARMA·Filed 2016·Application pending·0 cites
- 4940US2009169472A1Methods and compositions for treating immune disordersCANCER REC TECH LTD·Filed 2006·Application pending·0 cites
- 5038US2019153113A1Cd39 vascular isoform targeting agentsINNATE PHARMA·Filed 2016·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Carine Paturel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →